Clinical Trials for Celera

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Radiopharmaceutical Treatment of Advanced Kidney Cancer

Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure

PRostate Cancer Enhanced Diagnosis by Calibration Technology

A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

Feasibility Trial for a Right Ventricular Failure Platform Trial

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

Lutathera and ASTX727 in Neuroendocrine Tumours

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

EBRT + Lu-PSMA for N1M0 Prostate Cancer

[18F]FPIA PET/CT Imaging in Patients With Solid Tumours

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1

Natural History Study of Cutaneous Neurofibromas in People With NF1

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Real-Life Chronic Rhinosinusitis Outcome Registry

Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake

Post-Authorization Long-Term Safety Study of LUTATHERA

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Biobank For MS And Other Demyelinating Diseases